Current Report Filing (8-k)
October 04 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 4, 2019
Date of Report (Date of earliest event reported)
AEVI GENOMIC
MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
Common stock, par value $0.0001 per share
|
GNMX
|
Nasdaq Global Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item
1.01. Entry Into a Material Definitive Agreement.
On October 4, 2019,
Aevi Genomic Medicine, Inc. (the “Company”) entered into an agreement with The Children’s Hospital of Philadelphia
(“CHOP”) to extend the maturity date of that certain Secured Convertible Promissory Note dated as of March 29, 2019
(the “Note”), issued by the Company to CHOP in the original principal amount of $3,166,666.64 (the “Agreement”).
Pursuant to the Agreement, the maturity of the Note was extended until November 15, 2019, with an automatic further extension to
December 15, 2019, if the Company has entered into a definitive agreement concerning a financing of at least $20 million on or
prior to November 15, 2019. In addition, pursuant to the Agreement, the Company and CHOP agreed to amend (i) the Sponsored Research
Agreement, dated November 12, 2014, as amended to date, by and between Medgenics Medical Israel Ltd. (“Medgenics”)
and CHOP (the “SRA”), (ii) the License Agreement, dated November 12, 2014, by and between Medgenics and CHOP, as amended
to date, (iii) the License Agreement, dated September 9, 2015, by and between neuroFix, LLC (“neuroFix”) and CHOP,
as amended to date, (iv) the License Agreement, dated December 18, 2017, by and between Aevi and CHOP, (v) the License Agreement,
dated October 3, 2016, by and between Medgenics, Inc. and CHOP and (vi) the License Agreement, dated October 20, 2016, by and between
Medgenics, Inc. and CHOP; to return to CHOP certain intellectual property on which the Company is no longer focused and provide
that the SRA continues after June 30, 2020, only upon the mutual agreement of CHOP and the Company.
The foregoing description
of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement,
a copy of which the Company expects to file as an exhibit to the Company’s Annual Report on Form 10-K for the year ending
December 31, 2019.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael F. Cola
|
|
|
|
Name: Michael F. Cola
|
|
|
|
Title: President and Chief Executive Officer
|
|
Date: October 4, 2019
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Apr 2023 to Apr 2024